An official website of the United States government
Home
Name
Pylarify
Alternate Names
piflufolastat F 18
Abbreviations
None
Category
Other therapy
Subcategory
DO NOT CODE- NOT A TREATMENT
NSC Number
None
Primary Site
Prostate
Histology
None
Remarks
5/27/2021 FDA has approved Pylarify (piflufolastat F 18) – a drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. With the approval of Pylarify, certain men with prostate cancer will have greater access to PSMA-targeted PET imaging that can aid health care providers in assessing prostate cancer.
IMPORTANT NOTE: This drug was added to SEER*RX as reference only so that users know it's purpose in assessing prostate cancer. It is NOT a treatment.
IMPORTANT NOTE: This drug was added to SEER*RX as reference only so that users know it's purpose in assessing prostate cancer. It is NOT a treatment.
Coding
This drug should NOT be coded
